At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Effectiveness of CARE1.02 Spectacle Lens Versus Single-vision Spectacle Lens in Myopia Control: a Randomised Controlled Trial
In Brief
A clinical study evaluating CARE1.02 and Single-vision spectacle lens for Myopia. Completed, enrolled 796 participants across 1 site.
Detailed Summary
China is a major country in myopia, with the highest number of teenagers suffering from myopia. Controlling the progression of myopia and the related complications caused by axial elongation have clinical significance and social value. Currently. There is a lack of researches on the impact of specially designed myopia control spectacle lens in adolescents aged 12 and above. Therefore, The researchers plan to conduct a randomized controlled trial among myopia adolescents aged 12-17 in middle and high schools in Guangzhou, to test and verify the safety and effectiveness of CARE1.02 on myopia control compared with single-vision spectacle lens.
Study Details
Timeline
Interventions
Participants in the intervention group will wear CARE1.02 and receive the follow-up checks.
Participants in the control group will wear single-vision spectacle lens and receive the follow-up checks.